It is estimated that 10-20% of allergic rhinitis sufferers have a condition which is not well controlled despite the use of symptom-relieving medication. ALK's products can potentially benefit these patients.
A global disease
House dust mite allergy is the most common respiratory allergy, affecting around half of all people with a respiratory allergy. Furthermore, half of patients with house dust mite allergy suffer from both allergic rhinitis and allergic asthma, which illustrates the need to address both conditions.
At ALK we recognise the impact that living with an allergy that is not well-controlled can have on everyday life. Our commitment is to continue to evolve our products beyond symptom control to give allergy sufferers long-lasting relief with products and solutions that meet the needs of real-life.
Partnerships to leverage growth
To deliver on our commitment to patients ALK has entered into partnership agreements with Torii, Abbott and Seqirus to commercialise its latest products in Japan, Russia and South-East Asia, and Australia and New Zealand, respectively.